(S)-1-tritylaziridine-2-carboxylic acid | 84771-33-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (S)-1-tritylaziridine-2-carboxylic acid
• 英文别名: (S)-1-Tritylaziridine-2-carboxylic acid；(2S)-1-tritylaziridine-2-carboxylic acid
• CAS: 84771-33-5
• 化学式: C₂₂H₁₉NO₂
• 分子量: 329.398
• InChiKey: BXSIPZGNIBVSLK-AJZOCDQUSA-N

物化性质

• 沸点：
  470.3±45.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  40.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-1-tritylaziridine-2-carboxylic acid 在 TEA 、 N,N'-二环己基碳二亚胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 73.0h， 生成 Trt-Azy-Leu-Pro-OH
  参考文献：
  名称：

  On the synthesis of (2S)-aziridine-2-carboxylic acid containing peptides

  摘要：

  Optimized conditions are described for the synthesis of 1-trityl-2-aziridine-carboxylic acid 3 (Trt-Azy-OH) and benzyl (2S)-aziridine-2-carboxylate 6 (H-Azy-OBzl) as useful derivatives for the synthesis of N- and C-terminal aziridine-containing peptides. Thereby, the use of the pentafluorophenyl ester of Trt-Azy-OH was found to be the method of choice in acylating steps, whereas acylation of H-Azy-OBzl several classical methods of peptide synthesis can be successfully used. The fully protected aziridine-2-carboxylic acid peptides are accessible in satisfactory yields as analytically defined products, but partial or total deprotection of these compounds again by standard procedures of peptide synthesis is surprisingly difficult in terms of satisfactory yields, whereby sequence-dependent unstability both in the reaction and purification steps as well as on storage was found to strongly limit the accessibility of these aziridine-containing peptides as promising active-site inactivators of cysteine-proteinases.

  DOI：

  10.1016/s0040-4020(01)80847-4
• 作为产物：
  描述：

  (S)-(-)-1-三苯甲基-2-氮丙啶羧酸甲酯 在 lithium hydroxide 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 (S)-1-tritylaziridine-2-carboxylic acid
  参考文献：
  名称：

  Studies on 2-Aziridinecarboxylic Acid. VIII. Total Synthesis of Actinomycin D and Its Serine AnalogueviaRing-opening Reaction of 1-Benzyloxycarbonyl-2-aziridinecarboxylic Acid Moiety

  摘要：

  通过β-羟基-α-氨基酸肽与DEAD-TPP试剂的反应，直接合成了含有1-苄氧羰基-2-氮丙啶羧酸的肽，并通过氮丙啶与N-保护二肽的开环反应，制备了放线菌素D合成的关键O肽中间体。用 DCC-HOBt 法制备了肽内酯，随后的去苄基程序和氧化程序以良好的收率得到了标题化合物。

  DOI：

  10.1246/bcsj.55.3237

文献信息

• [EN] METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS<br/>[FR] MÉTHODES DE RETARDEMENT, DE PRÉVENTION ET DE TRAITEMENT DE LA RÉSISTANCE ACQUISE AUX INHIBITEURS DE RAS
  申请人：REVOLUTION MEDICINES INC

  公开号：WO2021257736A1

  公开（公告）日：2021-12-23

  The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors. Specifically, in some embodiments this disclosure includes compositions and methods for inducing apoptosis of tumor cells and/or for delaying, preventing, or treating acquired resistance to RAS inhibitors using bi-steric mTOR inhibitors.

  本公开涉及使用双-立体异构体mTOR抑制剂与RAS抑制剂联合治疗疾病或病状（例如，癌症）的配方和方法。具体而言，在某些实施方式中，本公开包括用于诱导肿瘤细胞凋亡和/或用于延迟、预防或治疗对RAS抑制剂获得性耐药性的双-立体异构体mTOR抑制剂的配方和方法。
• [EN] ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：NOVARTIS AG

  公开号：WO2016203432A1

  公开（公告）日：2016-12-22

  This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

  该应用程序披露了抗P-钙粘蛋白抗体、其抗原结合片段，以及所述抗体或抗原结合片段的抗体药物偶联物，特别是包括与奥利司他汀类似物偶联的抗P-钙粘蛋白抗体的抗体药物偶联物。该发明还涉及使用抗体药物偶联物治疗癌症的方法。本文还披露了制备抗体、抗原结合片段和抗体药物偶联物的方法，以及将抗体和抗原结合片段用作诊断试剂的方法。
• Catalytic carbonylation of three and four membered heterocycles
  申请人：——

  公开号：US20030162961A1

  公开（公告）日：2003-08-28

  Epoxides, aziridines, thiiranes, oxetanes, lactones, lactams and analogous compounds are reacted with carbon monoxide in the presence of a catalytically effective amount of catalyst having the general formula [Lewis acid] z+ {[QM(CO) x ] w− } y where Q is any ligand and need not be present, M is a transition metal selected from the group consisting of Groups 4, 5, 6, 7, 8, 9 and 10 of the periodic table of elements, z is the valence of the Lewis acid and ranges from 1 to 6, w is the charge of the metal carbonyl and ranges from 1 to 4 and y is a number such that w times y equals z, and x is a number such as to provide a stable anionic metal carbonyl for {[QM(CO) x ] w− } y and ranges from 1 to 9 and typically from 1 to 4.

  环氧化物、氮杂环丙烷、硫杂环丙烷、氧杂环丁烷、内酯、内酰胺和类似化合物在存在具有一定催化活性的催化剂的情况下与一般公式为[路易斯酸] z+ {[QM(CO) x ] w− } y的催化剂反应，其中Q是任何配体且不一定存在，M是从元素周期表的4、5、6、7、8、9和10族中选择的过渡金属，z是路易斯酸的化合价，范围从1到6，w是金属羰基的电荷，范围从1到4，y是一个数字，使得w乘以y等于z，x是一个数字，以提供稳定的阴离子金属羰基{[QM(CO) x ] w− } y，范围从1到9，通常从1到4。
• [EN] MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU PROTÉASOME
  申请人：UNIV CORNELL

  公开号：WO2019075259A1

  公开（公告）日：2019-04-18

  The compounds of the present invention are represented by the following compounds having Formula I and Formula (I'): where the substituents R1, R2, R2', R3, R4, R5, R', R", X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R', R", X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

  本发明的化合物由具有以下式I和式(I')的化合物表示，其中取代基R1、R2、R2'、R3、R4、R5、R'、R"、X、Y和Z如本文所定义，取代基R1、R2、R3、R4、R5、R'、R"、X、Y和Z如本文所定义。这些化合物用于治疗细菌感染、寄生虫感染、真菌感染、癌症、免疫紊乱、自身免疫性疾病、神经退行性疾病和紊乱、炎症性疾病，或肌肉萎缩症，或用于为移植的器官或组织提供免疫抑制。
• RAS INHIBITORS
  申请人：Revolution Medicines, Inc.

  公开号：US20210130326A1

  公开（公告）日：2021-05-06

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物，以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。